Mint Drops 10pp to 32% Odds of JUUL Relaunch Approval

---

JUUL's Best-Selling Flavor Ever Is Getting Priced Out of Its Own Comeback

JUUL's mint pod was, by every sales metric that mattered, the company's flagship product. Before its voluntary removal in November 2019, mint and menthol pods combined accounted for an estimated 70% or more of JUUL's total sales volume. Mint alone dominated the product line. If you were building a relaunch strategy based on proven demand, mint would be the first flavor you greenlight.

Prediction markets disagree. Mint's implied probability in the "What flavors will JUUL relaunch?" market has fallen from 42% to 32% over the past three days, a 10-percentage-point collapse that signals more than routine noise. The drop is the kind of breakout move that typically reflects a specific catalyst or a structural reassessment of odds. In this case, no single triggering event from the last 72 hours has been confirmed. What has changed, gradually and then all at once in market pricing, is a growing consensus that mint's extraordinary sales history is not an asset in the current regulatory environment. It is the single largest obstacle to its return.

The paradox is clean: the flavor JUUL sold the most is the flavor regulators scrutinized the most. Scrutiny, in an FDA premarket tobacco product application (PMTA) review, does not reward popularity. It punishes it.

---

What Happened to Mint Between 2019 and Now: The FDA's Unfinished Business With JUUL

JUUL's decision to pull mint in November 2019 was voluntary but not optional. As ABC15 reported at the time, the move came after a wave of research showing mint had become the dominant flavor among underage users, and Axios noted the halt was a direct response to mounting political and regulatory pressure. JUUL pulled mint before the FDA could force its hand, a strategic retreat designed to demonstrate corporate responsibility. That retreat created a permanent regulatory paper trail.

When the FDA issued its marketing denial order against JUUL in June 2022 (later stayed by a federal court), the agency's analysis leaned heavily on youth-appeal data. Much of that data was built on the mint era. Congressional testimony, CDC survey results, and media coverage from 2018 to 2019 all centered on mint as the vector through which underage vaping spread. The flavor appeared in more headlines, more hearing transcripts, and more regulatory filings than any other single JUUL SKU.

For any PMTA pathway, JUUL would need to demonstrate that reintroducing mint serves a net population-level health benefit, meaning it helps more adult smokers switch than it attracts new underage users. That argument is technically possible but politically toxic. JUUL Labs has published position papers on topics adjacent to menthol and tobacco product standards, but the regulatory posture toward characterizing flavors (particularly mint) as youth-appeal drivers has only hardened since 2019. No confirmed regulatory development in the last 72 hours explains the precise timing of the 10-point drop. The repricing appears to reflect a maturing market consensus rather than a single headline.

---

The Case for Mint: Why 32% Might Be Too Low

Dismissing mint entirely requires ignoring some stubborn facts. First, mint is not a "candy" or "fruit" flavor. Its sensory profile sits closer to menthol, which has a stronger argument for adult smoker appeal and switching efficacy. If JUUL's legal team can frame mint as a menthol-adjacent product rather than a youth-appeal flavor, the PMTA calculus changes. Second, the commercial incentive is enormous. No other flavor in JUUL's portfolio generated comparable revenue. A relaunch without mint would leave the company's highest-demand product permanently sidelined. Third, the FDA's own review framework, while cautious, does not categorically prohibit flavors. It requires evidence. JUUL has had years to assemble population-level switching data that could, in theory, satisfy the standard.

At 32%, the market is saying mint has roughly a one-in-three chance. That price embeds real skepticism but not outright dismissal. The strongest case against the current odds is that the political environment could shift before the December 31, 2026 resolution date: a change in FDA leadership priorities, a favorable court ruling, or new adult-switching data could all move the needle. If mint's probability touched 18% at its period low, the current 32% already represents a 14-percentage-point recovery from maximum pessimism. The question is whether that recovery has more room to run.

---

Track the Mint Relaunch Odds in Real Time

Mint currently trades at 32% implied probability across platforms, though the per-platform divergence is notable. Kalshi prices mint at 15%, while Polymarket shows 50%. That 35-point spread is wide enough to raise questions about differing trader bases and information flow, though the spread data should not be treated as reliable given liquidity differences between the two platforms. A further decline below 25% would signal that the market views mint as a true long shot. A recovery above 40% would suggest traders believe JUUL has found a viable regulatory pathway.

Prediction-market view

Live prices, venue by venue

Compare the latest YES price at each venue. Check market rules, liquidity, and fees before trading.

Mint

Consensus YES price across 1 venues

15%average

KalshiBest YES price16¢

Mango

Consensus YES price across 1 venues

6%average

KalshiBest YES price9¢

Cucumber

Consensus YES price across 1 venues

1%average

KalshiBest YES price9¢

Mint

Consensus YES price across 1 venues

52%average

PolymarketBest YES price98¢

This market resolves on December 31, 2026. Between now and then, the key variables are FDA posture toward flavored nicotine products, any public movement on JUUL's PMTA applications, and whether JUUL signals intent to include mint in a relaunch lineup. The irony of mint's position is structural: the same sales dominance that made it JUUL's most valuable product made it regulators' most visible target. At 32%, the market is pricing that irony as a liability. The question traders need to answer is whether that liability is temporary or permanent.